Pfizer will also have options to license the Israeli startup’s platform and disease models, and fund supplementary project support, in a deal potentially worth up to $110 million over the next five years
Read more here.
[CytoReason in Calcalist] CytoReason raises $20 million from Pfizer for AI drug discovery and development platform
Date:
Latest Intelligence
